

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Healthia Limited
ABN	85 626 087 223

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mrs Lisa Michelle Roach
Date of last notice	20 September 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	<ol style="list-style-type: none">1. Indirect2. Indirect3. Direct4. Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none">1. Matthew John Roach as trustee for The Roach Business Trust. Lisa Roach is the Principal and Primary Beneficiary of this trust.2. Roach Super (QLD) Pty Ltd as trustee for the Roach Super Fund. Lisa Roach is a director and shareholder of the trustee and a member of the Superannuation Fund.3. Lisa Michelle Roach4. Lisa Michelle Roach
Date of change	<ol style="list-style-type: none">1. Nil2. Nil3. 27 October 20224. 27 October 2022
No. of securities held prior to change	<ol style="list-style-type: none">1. 625,0712. 248,0553. 22,6934. 264,840
Class	<ol style="list-style-type: none">1. Ordinary Shares2. Ordinary Shares3. Ordinary Shares4. Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. 101,675 4. Nil
Number disposed	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. Nil 4. (a) 101,675 (b) 7,165
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. Nil - the shares are being issued following the vesting of Performance Rights under Healthia's Performance Rights Plan 4. (a) Nil - the shares are being issued following the vesting of Performance Rights under Healthia's Performance Rights Plan (b) Nil – performance rights under Healthia's Performance Rights Plan are cancelled for nil consideration.
No. of securities held after change	<ol style="list-style-type: none"> 1. 625,071 2. 248,055 3. 124,368 4. 156,000
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> 1. Nil 2. Nil 3. Issue of shares following the vesting of Performance Rights under Healthia's Performance Rights Plan 4. (a) Issue of shares following the vesting of Performance Rights under Healthia's Performance Rights Plan (b) Partial lapse of Performance Rights under Healthia's Performance Rights Plan

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.